Pfizer recalls all lots of anti-smoking drug over carcinogen presence By Reuters
(Reuters) – Pfizer Inc (NYSE:) said on Thursday it was recalling all lots of its anti-smoking treatment, Chantix, due to high levels of cancer-causing agents called nitrosamines in the pills.
Pfizer Inc (NYSE:) halted the distribution of Chantix in June and has already recalled several lots.
Pfizer requested distributors and wholesalers to immediately stop selling the tablet.
The company said there was no immediate risk to patients
taking Chantix, but advised them to consult with their health care provider to check the availability of alternative treatments.
Chantix was approved as a prescription drug by the FDA on May 6, 2006. The medication is used to aid adults over 18 who want to quit smoking. It can be taken for 12-24 weeks.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.